MARKET

DBVT

DBVT

DBV Tech
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.40
+0.13
+2.47%
Closed 16:00 03/03 EST
OPEN
5.34
PREV CLOSE
5.27
HIGH
5.44
LOW
5.29
VOLUME
151.81K
TURNOVER
--
52 WEEK HIGH
10.18
52 WEEK LOW
1.350
MARKET CAP
593.21M
P/E (TTM)
-2.8740
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
DBV Technologies to Report Full Year 2020 Financial Results on March 4, 2021
Montrouge, France, March 1, 2020 DBV Technologies to Report Full Year 2020 Financial Results on March 4, 2021 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced tha...
GlobeNewswire · 2d ago
DBV Technologies to Participate in Upcoming AAAAI 2021 Congress
Montrouge, France, February 24, 2021 DBV Technologies to Participate in Upcoming AAAAI 2021 Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced upcoming par...
GlobeNewswire · 02/24 06:30
DBV Technologies Announces Appointment of Michele F. Robertson as Chief Legal Officer
Feb 22, 2021 (GLOBE NEWSWIRE via COMTEX) -- Montrouge, France, February 22, 2021 DBV Technologies Announces Appointment of Michele F. Robertson as Chief...
GlobeNewswire · 02/22 06:30
DBV Technologies to Participate in SVB Leerink Global Partners Healthcare Conference
Feb 19, 2021 (GLOBE NEWSWIRE via COMTEX) -- Montrouge, France, February 19, 2021 DBV Technologies to Participate in SVB Leerink Global Partners Healthcare...
GlobeNewswire · 02/19 06:30
Agriculture IoT Market Research Report by Component, by Agriculture Type, by Application - Global Forecast to 2025 - Cumulative Impact of COVID-19
GlobeNewswire · 02/18 16:42
Monthly information regarding the total number of voting rights and total number of shares of the Company as of January 31, 2021
Feb 11, 2021 (GLOBE NEWSWIRE via COMTEX) -- Monthly information regarding the total number of voting rights and total number of shares of the Company as of...
GlobeNewswire · 02/11 21:30
Hemophilia A Drug Market Size Research Report 2021 by Growth Rate, Revenue Estimates, Market Dynamics, Industry Trends and Forecast to 2027 Says Absolute Reports
Feb 10, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." “Hemophilia A Drug Market” research report...
The Express Wire · 02/10 08:53
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
Jan 29, 2021 (GLOBE NEWSWIRE via COMTEX) -- AMF REGULATED INFORMATIONMontrouge, France, January 29, 2021 Half-Year Report on the DBV Technologies Liquidity...
GlobeNewswire · 01/29 21:30
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of DBVT. Analyze the recent business situations of DBV Tech through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average DBVT stock price target is 9.20 with a high estimate of 16.85 and a low estimate of 1.982.
EPS
Institutional Holdings
Institutions: 104
Institutional Holdings: 37.14M
% Owned: 33.81%
Shares Outstanding: 109.85M
TypeInstitutionsShares
Increased
9
474.30K
New
23
-1.59M
Decreased
9
681.61K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.99%
Pharmaceuticals & Medical Research
-1.89%
Key Executives
Chairman/Chief Executive Officer/Director
Pierre-Henri Benhamou
Chief Operating Officer
David Schilansky
Executive Vice President/General Counsel
Joan Schmidt
Chief Scientific Officer
Hugh Sampson
Vice President - Research & Development
Lucie Mondoulet
Vice President - Business Development
Nathalie Donne
Director of Marketing
Veronique Foutel
Other
Wence Agbotounou
Other
Bertrand Dupont
Other
Laurent Martin
Other
Pascale Ehouarn
Director
Michel de Rosen
Director
George Horner
Director
Mailys Ferrere
Director
Didier Hoch
Director
Chahra Louafi
Director
Rafaele Tordjman
  • Dividends
  • Splits
  • Insider Activity
No Data
About DBVT
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.

Webull offers kinds of DBV Technologies SA stock information, including NASDAQ:DBVT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DBVT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DBVT stock methods without spending real money on the virtual paper trading platform.